Literature DB >> 30361334

ACCORDION: Ensuring That We Hear the Music Clearly.

Muh Geot Wong1,2, Hiddo J L Heerspink3, Vlado Perkovic4,2.   

Abstract

Keywords:  Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; End Stage Kidney Disease; Lipids; Prevalence; Renal Insufficiency; Risk Factors

Mesh：

Substances：

Year:  2018        PMID： 30361334      PMCID： PMC6237047          DOI： 10.2215/CJN.11370918

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

Review 1.  Is doubling of serum creatinine a valid clinical 'hard' endpoint in clinical nephrology trials?

Authors:  H J Lambers Heerspink; V Perkovic; D de Zeeuw
Journal:  Nephron Clin Pract       Date:  2011-08-11

Review 2.  GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.

Authors:  Andrew S Levey; Lesley A Inker; Kunihiro Matsushita; Tom Greene; Kerry Willis; Edmund Lewis; Dick de Zeeuw; Alfred K Cheung; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2014-10-16       Impact factor: 8.860

3.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

Authors:  T M E Davis; R Ting; J D Best; M W Donoghoe; P L Drury; D R Sullivan; A J Jenkins; R L O'Connell; M J Whiting; P P Glasziou; R J Simes; Y A Kesäniemi; V J Gebski; R S Scott; A C Keech
Journal:  Diabetologia       Date:  2010-11-04       Impact factor: 10.122

4.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

5.  Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT).

Authors:  Lily Agrawal; Nasrin Azad; Gideon D Bahn; Ling Ge; Peter D Reaven; Rodney A Hayward; Domenic J Reda; Nicholas V Emanuele
Journal:  Diabetologia       Date:  2017-11-03       Impact factor: 10.122

6.  Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.

Authors:  Muh Geot Wong; Vlado Perkovic; John Chalmers; Mark Woodward; Qiang Li; Mark E Cooper; Pavel Hamet; Stephen Harrap; Simon Heller; Stephen MacMahon; Giuseppe Mancia; Michel Marre; David Matthews; Bruce Neal; Neil Poulter; Anthony Rodgers; Bryan Williams; Sophia Zoungas
Journal:  Diabetes Care       Date:  2016-03-22       Impact factor: 19.112

7.  Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.

Authors:  Vlado Perkovic; Hiddo Lambers Heerspink; John Chalmers; Mark Woodward; Min Jun; Qiang Li; Stephen MacMahon; Mark E Cooper; Pavel Hamet; Michel Marre; Carl Erik Mogensen; Neil Poulter; Giuseppe Mancia; Alan Cass; Anushka Patel; Sophia Zoungas
Journal:  Kidney Int       Date:  2013-01-09       Impact factor: 10.612

8.  Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.

Authors:  Amy K Mottl; John B Buse; Faramarz Ismail-Beigi; Ronald J Sigal; Carolyn F Pedley; Vasilios Papademetriou; Debra L Simmons; Lois Katz; Josyf C Mychaleckyj; Timothy E Craven
Journal:  Clin J Am Soc Nephrol       Date:  2018-10-25       Impact factor: 8.237

9.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

10.  Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.

Authors:  Sophia Zoungas; John Chalmers; Bruce Neal; Laurent Billot; Qiang Li; Yoichiro Hirakawa; Hisatomi Arima; Helen Monaghan; Rohina Joshi; Stephen Colagiuri; Mark E Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Liu Lisheng; Giuseppe Mancia; Michel Marre; David R Matthews; Carl E Mogensen; Vlado Perkovic; Neil Poulter; Anthony Rodgers; Bryan Williams; Stephen MacMahon; Anushka Patel; Mark Woodward
Journal:  N Engl J Med       Date:  2014-09-19       Impact factor: 91.245
  10 in total
  1 in total

Review 1.  Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

Authors:  Jean-Charles Fruchart; Michel P Hermans; Jamila Fruchart-Najib
Journal:  Curr Atheroscler Rep       Date:  2020-07-15       Impact factor: 5.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.